Is Nutex Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 5, significantly lower than the industry average, while the EV to EBITDA ratio is 2.82, indicating strong earnings relative to enterprise value. Additionally, the company boasts an impressive ROCE of 128.63% and ROE of 76.34%, reflecting exceptional profitability.
In comparison to its peers, Nutex Health, Inc. has a more favorable EV to EBITDA ratio than Fulgent Genetics, Inc., which is at -8.0743, and Talkspace, Inc., which is at -344.3683. This suggests that Nutex is performing better in terms of operational efficiency and value creation. Over the past year, Nutex Health has delivered a remarkable stock return of 326.80%, significantly outperforming the S&P 500's return of 14.08%, reinforcing the notion of its undervaluation.